COVID-19 Vaccines Clinical Trial
Official title:
Effect of a Third COVID-19 Booster on COVID-19 Infection Rate and Return to Works During Fifth Wave COVID-19 Among Health Care Workers
A new wave of COVID-19 infections, mainly caused by the Omicron/ Delta variant, has been sweeping the globe since the start of 2022. In response, the administration of a third dose of COVID-19 vaccine was considered to address potential waning immunity over time and reduced effectiveness against the Omicron/ Delta variant. The pandemic also resulted in many infections among health care workers (HCWs) and their households. In this study, a retrospective analysis would perform on risk of COVID-19 infection and their outcome in relation to their COVID-19 vaccination history by using the data repository from one of the Hong Kong private hospitals. HCWs were required to submit a standardized online self-declaration form for report of 1) demographic of the HCWs, 2) symptoms related history and 3) COVID-19 exposure history once they were COVID-19 confirmed by rapid antigen test against COVID-19 and/or polymerase chain reaction (PCR) test for COVID-19. Subsequent follow up such as contact tracing, COVID-19 PCR testing results of these HCWs and status of return to work were captured by the infection control team in a systematic manner.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05918939 -
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
|
Early Phase 1 | |
| Active, not recruiting |
NCT06272253 -
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
|
Early Phase 1 | |
| Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
| Recruiting |
NCT05185817 -
Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients
|
Phase 2 | |
| Not yet recruiting |
NCT04876885 -
The Future of Viral Communications: Video-Based Health Promotion Strategies for COVID-19 Vaccinations
|
N/A | |
| Active, not recruiting |
NCT05571657 -
COVID-19 Booster Dose Reminder/Recall for Adolescents
|
N/A | |
| Completed |
NCT04888793 -
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
|
||
| Completed |
NCT04881396 -
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
|
||
| Recruiting |
NCT04871165 -
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
|
||
| Active, not recruiting |
NCT05293665 -
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05405283 -
Randomized, Single-blinded, Multicenter Trial Comparing the Immune Response to a 2nd Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNTech) or Sanofi /GSK B.1.351 Adjuvanted Vaccine in Adults
|
Phase 3 | |
| Recruiting |
NCT05508477 -
UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)
|
Phase 3 | |
| Recruiting |
NCT05471635 -
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
|
||
| Recruiting |
NCT06282692 -
INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old
|
Phase 3 | |
| Completed |
NCT05406908 -
Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases
|
Phase 4 | |
| Recruiting |
NCT04895007 -
Comparative Evaluation of Covid-19 Vaccines Response
|
||
| Recruiting |
NCT05831826 -
Effectiveness and Safety of the Inactivated COVID-19 Vaccine in Thousands of Patients With Autoimmune Diseases in China
|
||
| Recruiting |
NCT05096260 -
Getting to Yes, Michigan! (G2YMI)
|
N/A | |
| Completed |
NCT04962906 -
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
|
Phase 2 | |
| Active, not recruiting |
NCT05027672 -
Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.
|
Phase 2 |